Moderna, Inc. Inventory Write-down
Moderna, Inc. (MRNA) reported Inventory Write-down of $41.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2026-07-31
- Moderna, Inc. inventory write-down for the quarter ending 2026-06-30 was $41.00M, a 7.89% increase year-over-year.
- Moderna, Inc. inventory write-down for the quarter ending 2026-03-31 was $38.00M, a 9.52% decline year-over-year.
- Moderna, Inc. inventory write-down for the quarter ending 2025-12-31 was $144.00M, a 25.39% decline year-over-year.
- Moderna, Inc. inventory write-down for the quarter ending 2025-09-30 was $67.00M, a 68.69% decline year-over-year.
- Moderna, Inc. inventory write-down for fiscal 2025 was $291.00M, a 41.21% decline from fiscal 2024.
- Moderna, Inc. inventory write-down for fiscal 2024 was $495.00M, a 77.50% decline from fiscal 2023.
- Moderna, Inc. inventory write-down for fiscal 2023 was $2.20B, a 69.23% increase from fiscal 2022.
- Moderna, Inc. inventory write-down for fiscal 2022 was $1.30B.
| Period end | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month |
|---|---|---|---|---|
| 2026-06-30 | $41.00M 10-Q · filed 2026-07-31 | $79.00M 10-Q · filed 2026-07-31 | $223.00M derived: sum of 3 quarters · filed 2026-07-31 | $290.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $38.00M 10-Q · filed 2026-05-01 | $182.00M derived: sum of 2 quarters · filed 2026-05-01 | $249.00M derived: sum of 3 quarters · filed 2026-05-01 | $287.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $144.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $211.00M derived: sum of 2 quarters · filed 2026-02-20 | $249.00M derived: sum of 3 quarters · filed 2026-07-31 | $291.00M 10-K · filed 2026-02-20 |
| 2025-09-30 | $67.00M 10-Q · filed 2025-11-06 | $105.00M derived: sum of 2 quarters · filed 2026-07-31 | $147.00M 10-Q · filed 2025-11-06 | $340.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $38.00M 10-Q · filed 2026-07-31 | $80.00M 10-Q · filed 2026-07-31 | $273.00M derived: sum of 3 quarters · filed 2026-07-31 | $487.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $42.00M 10-Q · filed 2026-05-01 | $235.00M derived: sum of 2 quarters · filed 2026-05-01 | $449.00M derived: sum of 3 quarters · filed 2026-05-01 | $463.00M derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $193.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $407.00M derived: sum of 2 quarters · filed 2026-02-20 | $421.00M derived: sum of 3 quarters · filed 2026-02-20 | $495.00M 10-K · filed 2026-02-20 |
| 2024-09-30 | $214.00M 10-Q · filed 2025-11-06 | $228.00M derived: sum of 2 quarters · filed 2025-11-06 | $302.00M 10-Q · filed 2025-11-06 | $558.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | $14.00M 10-Q · filed 2025-08-01 | $44.00M 10-Q · filed 2025-08-01 | $344.00M derived: sum of 3 quarters · filed 2026-02-20 | $1.64B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | $30.00M 10-Q · filed 2025-05-01 | $330.00M derived: sum of 2 quarters · filed 2026-02-20 | $1.63B derived: sum of 3 quarters · filed 2026-02-20 | $2.09B derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $300.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $1.60B derived: sum of 2 quarters · filed 2026-02-20 | $2.06B derived: sum of 3 quarters · filed 2026-02-20 | $2.20B 10-K · filed 2026-02-20 |
| 2023-09-30 | $1.30B 10-Q · filed 2024-11-07 | $1.76B derived: sum of 2 quarters · filed 2024-11-07 | $1.90B 10-Q · filed 2024-11-07 | $2.21B derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | $464.00M 10-Q · filed 2024-08-01 | $612.00M 10-Q · filed 2024-08-01 | $912.00M derived: sum of 3 quarters · filed 2025-02-21 | $1.25B derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | $148.00M 10-Q · filed 2024-05-02 | $448.00M derived: sum of 2 quarters · filed 2025-02-21 | $781.00M derived: sum of 3 quarters · filed 2025-02-21 | $1.28B derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | $300.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $633.00M derived: sum of 2 quarters · filed 2025-02-21 | $1.13B derived: sum of 3 quarters · filed 2025-02-21 | $1.30B 10-K · filed 2025-02-21 |
| 2022-09-30 | $333.00M 10-Q · filed 2023-11-03 | $832.00M derived: sum of 2 quarters · filed 2023-11-03 | $1.00B 10-Q · filed 2023-11-03 | $1.02B derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-06-30 | $499.00M 10-Q · filed 2023-08-03 | $689.00M 10-Q · filed 2023-08-03 | $688.00M derived: sum of 3 quarters · filed 2024-02-23 | $688.00M derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-03-31 | $189.00M 10-Q · filed 2023-05-04 | $189.00M derived: sum of 2 quarters · filed 2024-02-23 | $189.00M derived: sum of 3 quarters · filed 2024-02-23 | $189.00M derived: sum of 4 quarters · filed 2024-02-23 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $0.00 derived: sum of 2 quarters · filed 2024-02-23 | $0.00 derived: sum of 3 quarters · filed 2024-02-23 | $0.00 10-K · filed 2024-02-23 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-03 | $0.00 10-Q · filed 2022-08-03 | ||
| 2020-12-31 | $0.00 10-K · filed 2023-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |